The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 178 of the 179 references it cites were found in a registry or an index.
Abstract
Cholinergic synapses are ubiquitous in the human central nervous system. Their high density in the thalamus, striatum, limbic system, and neocortex suggest that cholinergic transmission is likely to be critically important for memory, learning, attention and other higher brain functions. Several lines of research suggest additional roles for cholinergic systems in overall brain homeostasis and plasticity. As such, the brain's cholinergic system occupies a central role in ongoing research related to normal cognition and age-related cognitive decline, including dementias such as Alzheimer's disease. The cholinergic hypothesis of Alzheimer's disease centres on the progressive loss of limbic and neocortical cholinergic innervation. Neurofibrillary degeneration in the basal forebrain is believed to be the primary cause for the dysfunction and death of forebrain cholinergic neurons, giving rise to a widespread presynaptic cholinergic denervation. Cholinesterase inhibitors increase the availability of acetylcholine at synapses in the brain and are one of the few drug therapies that have been proven clinically useful in the treatment of Alzheimer's disease dementia, thus validating the cholinergic system as an important therapeutic target in the disease. This review includes an overview of the role of the cholinergic system in cognition and an updated understanding of how cholinergic deficits in Alzheimer's disease interact with other aspects of disease pathophysiology, including plaques composed of amyloid-β proteins. This review also documents the benefits of cholinergic therapies at various stages of Alzheimer's disease and during long-term follow-up as visualized in novel imaging studies. The weight of the evidence supports the continued value of cholinergic drugs as a standard, cornerstone pharmacological approach in Alzheimer's disease, particularly as we look ahead to future combination therapies that address symptoms as well as disease progression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The FDA approved two anti-amyloid immunotherapies, lecanemab and donanemab, for “early-stage” AD, encompassing both stage 3 (MCI) and stage 4 (mild dementia).”
From A 2025 update on treatment strategies for the Alzheimer’s disease spectrum (2025) · cites this paper as [18]
In the citing paper
“Degeneration of cholinergic neurons is known to significantly contribute to cognitive decline in AD patients [132] and has been studied in a variety of genetic AD mouse models.”
From Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models (2020) · cites this paper as [132]
In the citing paper
“AChE contributes to acetylcholine depletion and may facilitate the formation of neurotoxic Aβ-AChE complexes38.”
From Small-molecule PCSK9 inhibition enhances BBB amyloid-β clearance and suppresses microglial inflammation in Alzheimer’s disease models (2026) · cites this paper as [38]
In the citing paper
“Cholinergic deficit also alters the permeability of the blood brain barrier causing erroneous transportation of metabolites and hampering the removal of amyloid plaque, worsening the disease condition [8].”
From Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease (2020) · cites this paper as [8]
In the citing paper
“From this point of view, AD could be prevented or effectively treated by decreasing the production of Aβ and tau; preventing aggregation or misfolding of these proteins; neutralizing or removing the toxic aggregate or misfolded forms of these proteins; or a combination of these modalities.7”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [7]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Perry, E. K., Tomlinson, B. E., Blessed, G., Bergmann, K., Gibson, P. H., & Perry, R. H. (1978) · BMJ · doi:10.1136/bmj.2.6150.1457 · Cited by 2,042
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844
Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., & DeLong, M. R. (1981) · Annals of Neurology · doi:10.1002/ana.410100203 · Cited by 1,736
Human Memory and the Cholinergic System: A Relationship to Aging?
Drachman, D. A. (1974) · Archives of Neurology · doi:10.1001/archneur.1974.00490320001001 · Cited by 1,397
NEUROTRANSMITTER-RELATED ENZYMES AND INDICES OF HYPOXIA IN SENILE DEMENTIA AND OTHER ABIOTROPHIES
BOWEN, D. M., SMITH, C. B., WHITE, P., & DAVISON, A. N. (1976) · Brain · doi:10.1093/brain/99.3.459 · Cited by 1,311
Research works printed but not linked: 1
- Geula, 1994, Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease, 263
Cited by
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Breijyeh, Z., & Karaman, R. (2020) · Molecules · doi:10.3390/molecules25245789 · Cited by 2,789
“As a result, the cholinergic hypothesis is based on three concepts: reduced presynaptic cholinergic markers in the cerebral cortex, severe neurodegeneration of nucleus basalis of Meynert (NBM) in the basal forebrain, which is the source of cortical cholinergic innervation, and the role of cholinergic antagonists in me…”
BackgroundZhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“100,101 Acetylcholine (ACh) is synthesized from choline and acetyl-coenzyme A by ChAT, then transported into synaptic vesicles through the vesicular acetylcholine transporter (VAChT).”
BackgroundSex differences in Alzheimer disease — the gateway to precision medicine
for the Women’s Brain Project and the Alzheimer Precision Medicine Initiative, Ferretti, M. T., Iulita, M. F., Cavedo, E., Chiesa, P. A., Schumacher Dimech, A., Santuccione Chadha, A., Baracchi, F., Girouard, H., Misoch, S., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0032-9 · Cited by 1,009
Self-citationCurrent and Future Treatments in Alzheimer Disease: An Update
Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966
Chen, Y., Xu, J., & Chen, Y. (2021) · Nutrients · doi:10.3390/nu13062099 · Cited by 917
“Its dysregulation is closely associated with neurodegenerative diseases such as AD [55,56].”
BackgroundRecent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease
Khan, S., Barve, K. H., & Kumar, M. S. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200528142429 · Cited by 820
“Cholinergic deficit also alters the permeability of the blood brain barrier causing erroneous transportation of metabolites and hampering the removal of amyloid plaque, worsening the disease condition [8].”
Background(2019) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-804766-8.00013-3 · Cited by 783
Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic
Hampel, H., O’Bryant, S. E., Molinuevo, J. L., Zetterberg, H., Masters, C. L., Lista, S., Kiddle, S. J., Batrla, R., & Blennow, K. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0079-7 · Cited by 716
Self-citationNew insights into atypical Alzheimer's disease in the era of biomarkers
Graff-Radford, J., Yong, K. X. X., Apostolova, L. G., Bouwman, F. H., Carrillo, M., Dickerson, B. C., Rabinovici, G. D., Schott, J. M., Jones, D. T., & Murray, M. E. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30440-3 · Cited by 706
Alzheimer's Disease: Treatment Strategies and Their Limitations.
Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., Malaplate, C., Yen, F. T., & Arab-Tehrany, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213954 · Cited by 689
“This includes a progressive loss of cholinergic innervation caused by dendritic, synaptic, and axonal degeneration [53,62].”
BackgroundInflammatory Processes in Alzheimer’s Disease—Pathomechanism, Diagnosis and Treatment: A Review
Twarowski, B., & Herbet, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076518 · Cited by 412
Hampel, H., Mesulam, M.-M., Cuello, A. C., Khachaturian, A. S., Vergallo, A., Farlow, M. R., Snyder, P. J., Giacobini, E., & Khachaturian, Z. S. (2019) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2018.43 · Cited by 369
Self-citationTherapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality
Hudry, E., & Vandenberghe, L. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.017 · Cited by 369
A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease
Hampel, H., Caraci, F., Cuello, A. C., Caruso, G., Nisticò, R., Corbo, M., Baldacci, F., Toschi, N., Garaci, F., Chiesa, P. A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00456 · Cited by 360
“, acetylcholinesterase inhibitors and non-competitive N-methyl-D-aspartate antagonists) have been approved for a symptomatic effect only and for the dementia stage of AD (4).”
BackgroundSelf-citationXie, C., Zhuang, X.-X., Niu, Z., Ai, R., Lautrup, S., Zheng, S., Jiang, Y., Han, R., Gupta, T. S., Cao, S., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00819-5 · Cited by 336
Walczak-Nowicka, Ł. J., & Herbet, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179290 · Cited by 335
Monteiro, A. R., Barbosa, D. J., Remião, F., & Silva, R. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115522 · Cited by 329
The effects of microglia-associated neuroinflammation on Alzheimer’s disease
Wang, C., Zong, S., Cui, X., Wang, X., Wu, S., Wang, L., Liu, Y., & Lu, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1117172 · Cited by 298
Fernández-Calle, R., Konings, S. C., Frontiñán-Rubio, J., García-Revilla, J., Camprubí-Ferrer, L., Svensson, M., Martinson, I., Boza-Serrano, A., Venero, J. L., Nielsen, H. M., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00566-4 · Cited by 278
Paudel, Y. N., Angelopoulou, E., Piperi, C., Othman, I., Aamir, K., & Shaikh, M. F. (2020) · Cells · doi:10.3390/cells9020383 · Cited by 257
The Pharmacological Action of Kaempferol in Central Nervous System Diseases: A Review
Silva dos Santos, J., Gonçalves Cirino, J. P., de Oliveira Carvalho, P., & Ortega, M. M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.565700 · Cited by 254
Shi, H., Ge, X., Ma, X., Zheng, M., Cui, X., Pan, W., Zheng, P., Yang, X., Zhang, P., Hu, M., et al. (2021) · Microbiome · doi:10.1186/s40168-021-01172-0 · Cited by 247
Microglia and Alzheimer’s Disease
Merighi, S., Nigro, M., Travagli, A., & Gessi, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112990 · Cited by 236
“While preventive and therapeutic solutions are still to be offered, treatments that just address symptoms have been established [2].”
BackgroundG-Protein-Coupled Receptors in Astrocyte–Neuron Communication
Kofuji, P., & Araque, A. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2020.03.025 · Cited by 236
Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches
Hussain, R., Zubair, H., Pursell, S., & Shahab, M. (2018) · Brain Sciences · doi:10.3390/brainsci8090177 · Cited by 229
New approaches to symptomatic treatments for Alzheimer’s disease
Cummings, J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00424-9 · Cited by 226
Endo-lysosomal dysregulations and late-onset Alzheimer’s disease: impact of genetic risk factors
Van Acker, Z. P., Bretou, M., & Annaert, W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0323-7 · Cited by 222
“Central to the AD pathology lies such a dysfunctional synaptic transmission with a widespread presynaptic cholinergic denervation as a consequence [56].”
Srivastava, P., Tripathi, P. N., Sharma, P., Rai, S. N., Singh, S. P., Srivastava, R. K., Shankar, S., & Shrivastava, S. K. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.049 · Cited by 221
Clemente-Suárez, V., Redondo-Flórez, L., Beltrán-Velasco, A., Ramos-Campo, D., Belinchón-deMiguel, P., Martinez-Guardado, I., Dalamitros, A., Yáñez-Sepúlveda, R., Martín-Rodríguez, A., & Tornero-Aguilera, J. (2023) · Biomedicines · doi:10.3390/biomedicines11092488 · Cited by 219
Microbial-derived metabolites as a risk factor of age-related cognitive decline and dementia
Connell, E., Le Gall, G., Pontifex, M. G., Sami, S., Cryan, J. F., Clarke, G., Müller, M., & Vauzour, D. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00548-6 · Cited by 208
“Its dysregulation is closely linked with AD [318].”
BackgroundNimgampalle, M., Chakravarthy, H., Sharma, S., Shree, S., Bhat, A. R., Pradeepkiran, J. A., & Devanathan, V. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101994 · Cited by 207
The Cholinergic System, the Adrenergic System and the Neuropathology of Alzheimer’s Disease
Bekdash, R. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031273 · Cited by 197
New Approaches for the Treatment of Alzheimer’s Disease
Fish, P. V., Steadman, D., Bayle, E. D., & Whiting, P. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.11.034 · Cited by 189
Reimagining cholinergic therapy for Alzheimer’s disease
Giacobini, E., Cuello, A. C., & Fisher, A. (2022) · Brain · doi:10.1093/brain/awac096 · Cited by 187
Self-citationGasiorowska, A., Wydrych, M., Drapich, P., Zadrozny, M., Steczkowska, M., Niewiadomski, W., & Niewiadomska, G. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.654931 · Cited by 184
Cholinergic System and Its Therapeutic Importance in Inflammation and Autoimmunity
Halder, N., & Lal, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660342 · Cited by 180
Astrocyte Senescence and Alzheimer’s Disease: A Review
Han, X., Zhang, T., Liu, H., Mi, Y., & Gou, X. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00148 · Cited by 177
Understanding the Gut–Brain Axis and Its Therapeutic Implications for Neurodegenerative Disorders
Zheng, Y., Bonfili, L., Wei, T., & Eleuteri, A. M. (2023) · Nutrients · doi:10.3390/nu15214631 · Cited by 175
Molecular and cellular mechanisms of selective vulnerability in neurodegenerative diseases
Kampmann, M. (2024) · Nature reviews. Neuroscience · doi:10.1038/s41583-024-00806-0 · Cited by 173
Costas‐Ferreira, C., & Faro, L. R. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168413 · Cited by 166
Benussi, A., Cantoni, V., Grassi, M., Brechet, L., Michel, C. M., Datta, A., Thomas, C., Gazzina, S., Cotelli, M. S., Bianchi, M., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26411 · Cited by 163
Innovative Therapy for Alzheimer’s Disease-With Focus on Biodelivery of NGF
Mitra, S., Behbahani, H., & Eriksdotter, M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00038 · Cited by 159
Cholinergic modulation of spatial learning, memory and navigation
Solari, N., & Hangya, B. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14089 · Cited by 157
MicroRNAs in Alzheimer's disease: Potential diagnostic markers and therapeutic targets
Liu, S., Fan, M., Zheng, Q., Hao, S., Yang, L., Xia, Q., Qi, C., & Ge, J. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112681 · Cited by 156
Fabiani, C., & Antollini, S. S. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00309 · Cited by 154
Moreira, N. C. D. S., Lima, J. E. B. D. F., Marchiori, M. F., Carvalho, I., & Sakamoto‐Hojo, E. T. (2022) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210061 · Cited by 153
Moss, D. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103438 · Cited by 146
Neurotransmitters in Prevention and Treatment of Alzheimer’s Disease
Yang, Z., Zou, Y., & Wang, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043841 · Cited by 145
Neurobiochemical Cross-talk Between COVID-19 and Alzheimer’s Disease
Rahman, M. A., Islam, K., Rahman, S., & Alamin, M. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02177-w · Cited by 136
Reconsideration of Anticholinesterase Therapeutic Strategies against Alzheimer’s Disease
Wang, H., & Zhang, H. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00391 · Cited by 136
Alzheimer's disease: Updated multi-targets therapeutics are in clinical and in progress
Sang, Z., Wang, K., Dong, J., & Tang, L. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114464 · Cited by 134
Yang, X., Yang, W., Xia, X., Lei, T., Yang, Z., Jia, W., Zhou, Y., Cheng, G., & Gao, H. (2022) · Small · doi:10.1002/smll.202203182 · Cited by 133
Transgenic Mouse Models of Alzheimer’s Disease: An Integrative Analysis
Sanchez-Varo, R., Mejias-Ortega, M., Fernandez-Valenzuela, J. J., Nuñez-Diaz, C., Caceres-Palomo, L., Vegas-Gomez, L., Sanchez-Mejias, E., Trujillo-Estrada, L., Garcia-Leon, J. A., Moreno-Gonzalez, I., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105404 · Cited by 129
Wu, J., Yu, Y., Wan, Y., Xia, J., Xu, J., Zhang, L., Liu, D., Chen, L., Tang, F., Ao, H., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113207 · Cited by 129
Abo-Zaid, O. A., Sallam, M. W., El-Sonbaty, S. M., Aziza, S., Emad, B., & Ahmed, E. S. A. (2022) · Biological Trace Element Research · doi:10.1007/s12011-021-03073-7 · Cited by 128
Alpha Power and Functional Connectivity in Cognitive Decline: A Systematic Review and Meta-Analysis
Lejko, N., Larabi, D. I., Herrmann, C. S., Aleman, A., & Ćurĉić‐Blake, B. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200962 · Cited by 127
The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
Du, H., Meng, X., Yao, Y., & Xu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1033479 · Cited by 125
Poudel, P., & Park, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040835 · Cited by 124
Tohma, H., Altay, A., Köksal, E., Gören, A. C., & Gülçın, İ. (2019) · Journal of Food Measurement & Characterization · doi:10.1007/s11694-019-00077-9 · Cited by 124
Cano, A., Turowski, P., Ettcheto, M., Duskey, J. T., Tosi, G., Sánchez-López, E., García, M. L., Camins, A., Souto, E. B., Ruiz, A., et al. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00864-x · Cited by 122
“Specifically, the degeneration of cholinergic neurons in the basal anterior brain has been reported to play a predominant role in the progression of the disease [118].”
BackgroundMajdi, A., Sadigh-Eteghad, S., Rahigh Aghsan, S., Farajdokht, F., Vatandoust, S. M., Namvaran, A., & Mahmoudi, J. (2020) · Reviews in the Neurosciences · doi:10.1515/revneuro-2019-0089 · Cited by 122
Toward noninvasive brain stimulation 2.0 in Alzheimer’s disease
Menardi, A., Rossi, S., Koch, G., Hampel, H. J., Vergallo, A., Nitsche, M. A., Stern, Y., Borroni, B., Cappa, S. F., Cotelli, M., et al. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101555 · Cited by 121
Self-citationThe cellular model for Alzheimer's disease research: PC12 cells
Xie, D., Deng, T., Zhai, Z., Sun, T., & Xu, Y. D. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1016559 · Cited by 118
Zhang, H., Wang, Y., Wang, Y., Li, X., Wang, S., & Wang, Z. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114606 · Cited by 117
López‐Ortiz, S., Pinto-Fraga, J., Valenzuela, P. L., Martín-Hernández, J., Seisdedos, M. M., García, Ó., Toschi, N., Giuliano, F. D., Garaci, F. G., Mercuri, N. B., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062897 · Cited by 115
Guo, Y., Zhu, X., Zeng, M., Qi, L., Tang, X., Wang, D., Zhang, M., Xie, Y., Li, H., Yang, X., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01443-2 · Cited by 115
Theories of Aging and the Prevalence of Alzheimer’s Disease
Trevisan, K., Cristina-Pereira, R., Silva-Amaral, D., & Aversi-Ferreira, T. A. (2019) · BioMed Research International · doi:10.1155/2019/9171424 · Cited by 111
Iliyasu, M. O., Musa, S. A., Oladele, S. B., & Iliya, A. I. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1081938 · Cited by 111
Wang, J., Yang, Y., Shi, Y., Wei, L., Gao, L., & Liu, M. (2024) · Environment International · doi:10.1016/j.envint.2024.108523 · Cited by 110
New Insights Into Cholinergic Neuron Diversity
Ahmed, N. Y., Knowles, R., & Dehorter, N. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00204 · Cited by 108
The Brain NGF Metabolic Pathway in Health and in Alzheimer’s Pathology
Cuello, A. C., Pentz, R., & Hall, H. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00062 · Cited by 108
Self-citationCell models for Alzheimer’s and Parkinson’s disease: At the interface of biology and drug discovery
Cetin, S., Knez, D., Gobec, S., Kos, J., & Pišlar, A. H. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112924 · Cited by 107
New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer’s disease
Zhang, F., Zhong, R.-J., Cheng, C., Li, S., & Le, W.-D. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00565-5 · Cited by 105
“On the other hand, acetylcholine is a major neurotransmitter in brain areas including the cortex, basal ganglia, and basal forebrain, and cholinergic transmission is critical for memory, learning, attention, and other higher brain functions [25].”
BackgroundSabbagh, M. N., Boada, M., Borson, S., Chilukuri, M., Doraiswamy, P. M., Dubois, B., Ingram, J., Iwata, A., Porsteinsson, A. P., Possin, K. L., et al. (2020) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2020.19 · Cited by 105
Self-citationScopolamine promotes neuroinflammation and delirium-like neuropsychiatric disorder in mice
Cheon, S. Y., Koo, B., Kim, S. Y., Kam, E. H., Nam, J., & Kim, E. J. (2021) · Scientific Reports · doi:10.1038/s41598-021-87790-y · Cited by 105
Li, T., Lu, L., Pember, E., Li, X., Zhang, B., & Zhu, Z. (2022) · Cells · doi:10.3390/cells11121925 · Cited by 104
The Alzheimer Precision Medicine Initiative
Hampel, H., ESCOTT-PRICEVal, A. P. M. I. (. A. F. (. B. B. B. B. L. (. A. B. L. W. (. B. B. C. C. C. C. C. A. (. C.-C. C. C. C. L. (. V. D. D. D., Vergallo, A., Perry, G., & Lista, S. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-181121 · Cited by 103
Self-citationAli, A. M., & Kunugi, H. (2020) · Antioxidants · doi:10.3390/antiox9100937 · Cited by 103
Igartúa, D. E., Martinez, C. S., Alonso, S. D. V., & Prieto, M. J. (2020) · AAPS PharmSciTech · doi:10.1208/s12249-020-01652-w · Cited by 102
Fanlo-Ucar, H., Picón-Pagès, P., Herrera-Fernández, V., ILL‐Raga, G., & Muñoz, F. J. (2024) · Antioxidants · doi:10.3390/antiox13101208 · Cited by 101
Wan, T., Wang, Z., Luo, Y., Zhang, Y., He, W., Mei, Y., Xue, J., Li, M., Pan, H., Li, W., et al. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/8239642 · Cited by 100
Nerve Growth Factor Pathobiology During the Progression of Alzheimer’s Disease
Mufson, E. J., Counts, S., Ginsberg, S. D., Mahady, L. J., Perez, S. E., Massa, S. M., Longo, F. M., & Ikonomović, M. D. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00533 · Cited by 99
González, J. F., Alcántara, A. R., Doadrio, A. L., & Sánchez-Montero, J. M. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1623201 · Cited by 98
Role of Chemokines in the Development and Progression of Alzheimer’s Disease
Wojcieszak, J., Kuczyńska, K., & Zawilska, J. B. (2022) · Journal of Molecular Neuroscience · doi:10.1007/s12031-022-02047-1 · Cited by 97
Pharmacological Treatment of Vascular Dementia: A Molecular Mechanism Perspective
Kuang, H., Zhou, Z., Zhu, Y., Wan, Z., Yang, M.-W., Hong, F., & Yang, S. (2021) · Aging and Disease · doi:10.14336/ad.2020.0427 · Cited by 97
Chang, E. H., Chavan, S. S., & Pavlov, V. A. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00263 · Cited by 97
Sang, Z., Wang, K., Shi, J., Cheng, X., Zhu, G., Wei, R., Ma, Q., Yu, L., Zhao, Y., Tan, Z., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111958 · Cited by 97
Zhou, Y., Qian, C., Tang, Y., Song, M., Zhang, T., Dong, G., Zheng, W., Yang, C., Zhong, C., Wang, A., et al. (2023) · Phytotherapy Research · doi:10.1002/ptr.7966 · Cited by 97
Ferreira, J. P. S., Albuquerque, H. M. T., Cardoso, S. M., Silva, A. M. S., & Silva, V. L. M. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113492 · Cited by 96
Stratoulias, V., Ruiz, R., Kanatani, S., Osman, A. M., Keane, L., Armengol, J. A., Rodríguez-Moreno, A., Murgoci, A.-N., García-Domínguez, I., Alonso-Bellido, I., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01326-3 · Cited by 96
Zeng, P. H., Wang, X., Ye, C., Su, H.-F., & Tian, Q. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073612 · Cited by 94
Role of Calcium Modulation in the Pathophysiology and Treatment of Alzheimer’s Disease
Baracaldo-Santamaría, D., Avendaño-Lopez, S. S., Ariza-Salamanca, D. F., Rodríguez-Giraldo, M., Calderón‐Ospina, C., González-Reyes, R. E., & Nava-Mesa, M. O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24109067 · Cited by 93
Sun, Q., Zhang, J., Li, A., Yao, M., Liu, G., Chen, S., Luo, Y., Wang, Z., Gong, H., Li, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28493-4 · Cited by 93
Bhat, B. A., Almilaibary, A., Mir, R. A., Aljarallah, B. M., Mir, W. R., Ahmad, F., & Mir, M. A. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.884345 · Cited by 93
Moringa oleifera : A Tree of Life as a Promising Medicinal Plant for Neurodegenerative Diseases
Ghimire, S., Subedi, L., Acharya, N., & Gaire, B. P. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c04581 · Cited by 90
Sang, Z., Wang, K., Zhang, P., Shi, J., Liu, W., & Tan, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.07.021 · Cited by 89
Evaluation of Rivastigmine in Alzheimer’s Disease
Nguyen, K., Hoffman, H., Chakkamparambil, B., & Grossberg, G. T. (2021) · Neurodegenerative Disease Management · doi:10.2217/nmt-2020-0052 · Cited by 89
Self-citationBile acids and neurological disease
Hurley, M. J., Bates, R., Macnaughtan, J., & Schapira, A. H. V. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108311 · Cited by 88
Cichoń, N., Grabowska, W. A., Gorniak, L., Stela, M., Harmata, P., Ceremuga, M., & Bijak, M. (2024) · Nutrients · doi:10.3390/nu17010078 · Cited by 88
Barbosa, D. C. D. S., Holanda, V. N., Assis, C. R. D., de Aguiar, J. C. R. D. O. F., doNascimento, P. H., da Silva, W. V., Navarro, D. M. D. A. F., da Silva, M. V., Lima, V. L. D. M., & Correia, M. T. D. S. (2020) · Industrial Crops and Products · doi:10.1016/j.indcrop.2020.112372 · Cited by 87
Metadata
- Authors
- Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., & Khachaturian, Z. S.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Northwestern University (US)
- McGill University (CA)
- Indiana University School of Medicine (US)
- University Hospital of Geneva (CH)
- Saint Louis University (US)
- Prevent Alzheimer’s Disease 2020 (US)
- University of Rhode Island (US)
- Corresponding author
- Hampel, Harald
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-05-29
- Volume
- 141
- Issue
- 7
- Pages
- 1917-1933
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC6022632
- OpenAlex
- W2805257646
- Cited by
- 1,918
- References
- 179
- Citations by year
- 2026: 245 · 2025: 298 · 2024: 298 · 2023: 328 · 2022: 300 · 2021: 228 · 2020: 130 · 2019: 65 · 2018: 21
- FWCI
- 14.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Brain (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Purdue University Indianapolis (Indiana University) (submittedVersion)
- Funders
- AXA Research Fund
- ‘Fondation pour la Recherche sur Alzheimer’, Paris, France. Ce travail a bénéficié d'une aide de l’Etat ‘Investissements d’avenir’ (ANR-10-IAIHU-06)
- ‘Investissements d’avenir’ (ANR-10-IAIHU-06)
- Canadian Institutes of Health Research
- National Research Council
- Alzheimer Society of Canada
- Rotary Club Livorno ‘Mascagni’/The Rotary Foundation (GG1758249)
- ADC (AG013854)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, cholinergic system, cholinergic hypothesis, cholinesterase inhibitors, acetylcholine, cholinergic denervation, neurofibrillary degeneration, amyloid plaques, cognitive decline, cholinergic drugs, combination therapy
- MeSH terms
- Alzheimer Disease, Cholinesterase Inhibitors, Cognition, Cognition Disorders, Humans, Amyloid beta-Peptides, Neurofibrillary Tangles, Cholinergic Agents, Cholinergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.